大剂量阿托伐他汀在冠心病患者介入术后的疗效观察

目的：观察大剂量阿托伐他汀在冠心病患者介入术后的疗效及安全性。方法：选择74例成功冠脉介入治疗术后患者随机分为两组,在常规治疗基础上治疗组采用阿托伐他汀80mg/d、对照组采用阿托伐他汀20mg/d,观察两组患者用药后3个月的心脏缺血事件、血脂和高敏C反应蛋白水平（hs-CRP）及不良反应。结果：心脏缺血事件的发生率治疗组低于对照组,有显著性差异（P〈0.05）。血脂和C反应蛋白水平降低治疗组好于对照组,有显著性差异（P〈0.05）。服药1个月后两组（治疗组6例、对照组4例）均有谷丙转氨酶轻度升高,两组间无显著性差异（P〉0.05）。结论：大剂量阿托伐他汀用于冠心病患者介入术后疗效显著,无严重不良反应。

Clinical observation of high -dose Atorvastatin in patients with coronary heart disease after intervention

Objective：To observe the efficacy and safety of high-dose Atorvastatin in patients with coronary heart disease after intervention. Methods：74 patients after successful coronary intervention were randomly divided into two groups,based on the conventional therapy the treatment group with Atorvastatin 80 mg/d and the control group with Atorvastatin 20 mg/d,the ischemic event,blood lipids and high sensitivity C reactive protein（hs-CRP） ,and adverse reactions of two groups were observed after 3 months. Results：The incidence of cardiac ischemic events in treatment group was lower than the control group,there was significant difference（P〈0.05） .Lipids and C-reactive protein levels decreased in treatment group was better than the control group,there was significant difference（P〈0.05） . Medication groups after 1 month [treatment group（6 cases） ,control group（4 cases） ] had slightly elevated alanine aminotransferase,there was no significant difference between the two groups（P〉0.05） . Conclusion：High-dose Atorvastatin therapy in patients after coronary intervention has notable curative effect and no serious side effects.